Baxalta options rights to six immuno-oncology projects from Symphogen; could pay up to $1.78bn
Symphogen AS granted Baxalta Inc. options to exclusively license global rights to six immuno-oncology projects against undisclosed checkpoint targets. Specific targets and indications were not disclosed.
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.